Yanhong Zhang

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells
    Yanhong Zhang
    Department of Pathology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
    Breast Cancer Res 7:R1080-9. 2005
  2. pmc Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1
    Wei Huang
    Department of Pathology, University of Michigan Medical School, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0605, USA
    Am J Pathol 172:893-904. 2008
  3. pmc WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48108, USA
    Neoplasia 6:179-85. 2004
  4. ncbi request reprint WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, Univeristy of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res 6:R110-5. 2004
  5. ncbi request reprint WISP3 is a novel tumor suppressor gene of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0054, USA
    Oncogene 21:3172-80. 2002
  6. pmc WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res 6:R110-5. 2004
  7. pmc Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition
    Yanhong Zhang
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
    Mod Pathol 25:178-84. 2012
  8. ncbi request reprint CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer
    Celina G Kleer
    Department of Pathology, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Mich 48109, USA
    Cells Tissues Organs 185:95-9. 2007
  9. pmc Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability
    Celina G Kleer
    Department of Pathology, Division of Hematology and Oncology, 2G332 University Hospital, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0054, USA
    Am J Pathol 160:579-84. 2002
  10. ncbi request reprint Enhanced suicide gene therapy by chimeric tumor-specific promoter based on HSF1 transcriptional regulation
    Jinhui Wang
    Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai 200031, PR China
    FEBS Lett 546:315-20. 2003

Collaborators

Detail Information

Publications15

  1. pmc Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells
    Yanhong Zhang
    Department of Pathology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
    Breast Cancer Res 7:R1080-9. 2005
    ..We hypothesized that inhibition of CCN6 might result in the loss of a growth regulatory function that protects mammary epithelial cells from the tumorigenic effects of growth factors, particularly IGF-1...
  2. pmc Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1
    Wei Huang
    Department of Pathology, University of Michigan Medical School, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0605, USA
    Am J Pathol 172:893-904. 2008
    ..Together, our results lead to a new hypothesis that Snail and ZEB1 are downstream of CCN6 and play a critical role in CCN6-mediated regulation of E-cadherin in breast cancer...
  3. pmc WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48108, USA
    Neoplasia 6:179-85. 2004
    ....
  4. ncbi request reprint WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, Univeristy of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res 6:R110-5. 2004
    ..We have demonstrated that WISP3 has tumor growth and angiogenesis inhibitory functions in IBC. We proposed that RhoC and WISP3 cooperate in the development of IBC...
  5. ncbi request reprint WISP3 is a novel tumor suppressor gene of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0054, USA
    Oncogene 21:3172-80. 2002
    ..Our data demonstrate that WISP3 acts as a tumor suppressor gene in the breast. Loss of WISP3 expression contributes to the phenotype of IBC by regulating tumor cell growth, invasion and angiogenesis...
  6. pmc WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res 6:R110-5. 2004
    ..We have demonstrated that WISP3 has tumor growth and angiogenesis inhibitory functions in IBC. We hypothesized that RhoC and WISP3 cooperate in the development of IBC...
  7. pmc Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition
    Yanhong Zhang
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
    Mod Pathol 25:178-84. 2012
    ..05). We provide first in situ evidence that epithelial to mesenchymal transition inducers and tumor-initiating cells are present specifically in the non-glandular components of metaplastic carcinomas...
  8. ncbi request reprint CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer
    Celina G Kleer
    Department of Pathology, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Mich 48109, USA
    Cells Tissues Organs 185:95-9. 2007
    ..This review will focus on the current knowledge regarding the function of CCN6 in breast cancer with special emphasis on the emerging role of CCN6 as a regulator of the epithelial phenotype and E-cadherin expression in the breast...
  9. pmc Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability
    Celina G Kleer
    Department of Pathology, Division of Hematology and Oncology, 2G332 University Hospital, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0054, USA
    Am J Pathol 160:579-84. 2002
    ..RhoC is specifically expressed in invasive breast carcinomas capable of metastasizing, and it may be clinically useful in patients with tumors smaller than 1 cm to guide treatment...
  10. ncbi request reprint Enhanced suicide gene therapy by chimeric tumor-specific promoter based on HSF1 transcriptional regulation
    Jinhui Wang
    Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai 200031, PR China
    FEBS Lett 546:315-20. 2003
    ..These results indicate that the hTERT-cHSF1/HSE promoter is highly tumor-specific and strong with potential application in targeted gene therapy, and therefore may be useful for construction of vectors for systemic therapy...
  11. ncbi request reprint Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer
    Lili Zhao
    Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    Hum Gene Ther 16:845-58. 2005
    ..These data indicated that oncolytic adenovirus expressing IL-24 could exert potential antitumor activity and offer a novel approach to cancer therapy...
  12. ncbi request reprint Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy
    Yanhong Zhang
    Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China
    Cancer Res 66:4291-8. 2006
    ..In conclusion, our dual gene virotherapy completely eliminated colorectal tumor xenografts via enhanced apoptosis, and this novel strategy points toward a new direction of cancer treatment...
  13. ncbi request reprint Formation of CdS nanoparticle necklaces with functionalized dendronized polymers
    Yanhong Zhang
    State Key Laboratory of Polymer Physics and Chemistry, Joint Laboratory of Polymer Sciences and Materials Institute of Chemistry, The Chinese Academy of Sciences, Beijing 100080, China
    Small 2:1314-9. 2006
    ..CdS nanoparticle necklaces were obtained successfully when polymers bearing second-generation dendrons were applied...
  14. ncbi request reprint S-nitrosohemoglobin: a biochemical perspective
    Yanhong Zhang
    Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
    Free Radic Biol Med 36:947-58. 2004
    ....
  15. ncbi request reprint Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer
    Yiqun Zhang
    Department of General Surgery, Zhongshan Hospital of Fudan University, Shanghai 200032, China
    J Cancer Res Clin Oncol 134:219-26. 2008
    ..The tumor cannot be completely eradicated only with ZD55-MnSOD, although ZD55-MnSOD has obvious antitumor activity. 5-fluorouracil (5-FU) is still the most effective adjuvant therapy for patients with colorectal cancer...